28466-95-7

Upstream product

• 95-92-1 oxalic acid diethyl ester 
• 490-78-8 2,5-Dihydroxyacetophenone 

Downstream Products

• 1027898-47-0 6-{3-[4-(Hydroxy-diphenyl-methyl)-piperidin-1-yl]-propoxy}-4-oxo-4H-chromene-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

ANTI-INFECTIVE AGENTS

The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula (I), o

2-oxadiazolechromone derivatives

2-Oxadiazolyl-chromone derivatives (I) are new. 2-Oxadiazolyl-chromone derivatives of formula (I) and their derivatives, solvates and stereoisomers are new. R = A, phenyl (optionally substituted with 1-5 of R1) or pyridyl; X = H, OH, OA, phenoxy, Ar, OCOA

Chromenon derivatives

The use of 2-(heterocyclyl-carbonyl)-chromen-4-one derivatives (I) as kinase signal transduction inhibiting, regulating and/or modulating medicaments is new. Some of the compounds (I) are new. The use of chromenone derivatives of formula (I) or their derivatives, solvates, salts or stereoisomers (including mixtures in all proportions) is claimed in the production of kinase signal transduction inhibiting, regulating and/or modulating medicaments. [Image] R 1>-R 3>H, OH, OA, phenoxy, Ar, OCOA, SO 3H, SO 3A, OSO 3H, OSO 3A, SO 2A, halo, COOH, COOA, CONH 2, NHSO 2A, COA, CHO or SO 2NH 2; or R 1>+R 2>OCH 2O or OCH 2CH 2O; Het : mono- or bicyclic, saturated, unsaturated or aromatic heterocycle containing 1-4 N, O or S heteroatoms, optionally substituted by 1-3 of =O, =S, =NH, halo, A, -(CH 2) o-Ar, -(CH 2) o-cycloalkyl, -(CH 2) o-OH, -(CH 2) o-NH 2, NO 2, CN, -(CH 2) o-COOH, -(CH 2) o-COOA, -(CH 2) o-CONH 2, -(CH 2) o-NHCOA, NHCONH 2, -(CH 2) o-NHSO 2A, CHO, COA', SO 2NH 2and/or S(O) oA; Ar : phenyl, naphthyl or biphenylyl (all optionally substituted by 1-3 of halo, A, OH, OA, NH 2, NO 2, CN, COOH, COOA, CON 2, NHCOA, NHCONH 2, NHSO 2A, CHO, COA, SO 2NH 2or S(O) oA); A : 1-10C alkyl (optionally substituted by 1-7 F); A' : 1-6C alkyl or benzyl; o : 0-2. Independent claims are included for: (a) (I) (including salts etc.) as new compounds, provided that R 1>is other than H or halo; and (b) the preparation of the new compounds (I). ACTIVITY : Cytostatic; ophthalmological; antidiabetic; antiinflammatory; antirheumatic; antiarthritic; antipsoriatic; dermatological; antiallergic; osteopathic; gynecological; vulnerary; immunosuppressive; immunostimulant; anti-HIV; nootropic; neuroprotective; antiarteriosclerotic; cardiant; vasotropic; cerebroprotective. MECHANISM OF ACTION : Tyrosine kinase inhibitor; Raf kinase inhibitor; antioxidant. 6-Hydroxy-2-(3,5-dichloropyrazine-2-carbonyl)-chromen-4-one (Ia) had IC 509.64 MicroM for inhibition of protein kinase B (PKB).